HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Testing Finds Consumer Health Market Problems, But It Can’t Test Entire Marketplace

Executive Summary

CDER compliance office director Donald Ashley offers a cautionary note to temper expectations for the FDA’s enforcement in the supplement sector. “We continue to warn the public about products very often sold as dietary supplements that contain hidden drugs,” he says.

You may also be interested in...



‘Go Try To Find Some Zinc Gluconate’: The Dietary Supplement Supply Chain Entering 2022

Ingredients for immune health supplements are in short supply as high demand persists in the US. CEOs Mark LeDoux of Natural Alternatives International and Jim Emme of NOW Health Group, both on the Natural Products Association’s board of directors, discuss ongoing supply issues and best practices to avoid problems.

OTC Sanitizer Contaminations Drop In US As Auxiliary Manufacturers Stop Production

"Fewer people are manufacturing the products ... That seems to be a sort of a natural reaction to I think the decreased consumer demand," says Donald Ashley, compliance chief in FDA’s drug center.

Amazon Response About Drug-Spiked Supplements ‘Not Sufficient To Protect Public’ – FDA

“Amazon has taken some action when alerted by the FDA about sales” of violative supplements, but FDA "found that other such products continue to be offered for sale” by the firm through its Fulfillment by Amazon service, according to untitled letter.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS151769

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel